Literature DB >> 32833755

Liver Resection for Early Hepatocellular Carcinoma: Preoperative Predictors of Non Transplantable Recurrence and Implications for Treatment Allocation.

Maximiliano Gelli1, Mylène Sebagh2, Raphaël Porcher3, Elena Romanelli1, Eric Vibert1, Antonio Sa Cunha1, Denis Castaing1, Olivier Rosmorduc1, Didier Samuel1, René Adam1, Daniel Cherqui1.   

Abstract

BACKGROUND AND AIMS: LR and LT are the standard curative options for early HCC. LT provides best long-term survival but is limited by organ shortage. LR, readily available, is hampered by high recurrence rates. Salvage liver transplantation is an efficient treatment of recurrences within criteria. The aim of the study was to identify preoperative predictors of non transplantable recurrence (NTR) to improve patient selection for upfront LR or LT at initial diagnosis. STUDY
DESIGN: Consecutive LR for transplantable HCC between 2000 and 2015 were studied. A prediction model for NTR based on preoperative variables was developed using sub-distribution hazard ratio after multiple imputation and internal validation by bootstrapping. Model performance was evaluated by the concordance index after correction for optimism.
RESULTS: A total of 148 patients were included. Five-year overall survival and recurrence free survival were 73.6% and 29.3%, respectively (median follow-up 45.8 months). Recurrence rate was 54.8%. NTR rate was 38.2%. Preoperative model for NTR identified >1 nodule [sub-distribution hazard ratio 2.35 95% confidence interval (CI) 1.35-4.09], AFP >100 ng/mL (2.14 95% CI 1.17-3.93), and F4 fibrosis (1.93 95% CI 1.03-3.62). The apparent concordance index of the model was 0.664 after correction for optimism. In the presence of 0, 1, and ≥2 factors, NTR rates were 2.6%, 22.7%, and 40.9%, respectively. The number of prognostic factors was significantly associated with the pattern of recurrence (P = 0.001) and 5-year recurrence free survival (P < 0.001).
CONCLUSIONS: Cirrhosis, >1 nodule, and AFP >100 ng/mL were identified as preoperative predictors of NTR. In the presence of 2 factors or more upfront transplantation should be probably preferred to resection in regard of organ availability. Other patients are good candidates for LR and salvage liver transplantation should be encouraged in eligible patients with recurrence.

Entities:  

Mesh:

Year:  2020        PMID: 32833755     DOI: 10.1097/SLA.0000000000004259

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  5 in total

1.  Preoperative predictors of non-transplantable recurrence after resection for early-stage hepatocellular carcinoma: application in an East Asian cohort.

Authors:  Wei-Feng Li; Yi-Hao Yen; Yueh-Wei Liu; Chih-Chi Wang; Chee-Chien Yong; Chih-Che Lin
Journal:  Updates Surg       Date:  2022-01-13

2.  Comparison of portal and capsular microscopic vascular invasion in the outcomes of early HCC after curative resection.

Authors:  Ding-Sen Huang; Ting-Ting Liu; Wei-Ting Lu; Chih-Chi Wang; Chih-Che Lin; Chee-Chen Yong; Kuang-Den Chen; Yueh-Wei Liu; Yuan-Hung Kuo; Yi-Hao Yen; Tsung-Hui Hu; Ming-Chao Tsai
Journal:  Am J Cancer Res       Date:  2022-06-15       Impact factor: 5.942

3.  5-year recurrence prediction after hepatocellular carcinoma resection: deep learning vs. Cox regression models.

Authors:  Hon-Yi Shi; King-The Lee; Chong-Chi Chiu; Jhi-Joung Wang; Ding-Ping Sun; Hao-Hsien Lee
Journal:  Am J Cancer Res       Date:  2022-06-15       Impact factor: 5.942

4.  Long non‑coding RNA ZSCAN16‑AS1 promotes the malignant properties of hepatocellular carcinoma by decoying microRNA‑451a and consequently increasing ATF2 expression.

Authors:  Chaohua Lv; Qingsong Wan; Chengxiang Shen; Hongsheng Wu; Bin Zhou; Weiwei Wang
Journal:  Mol Med Rep       Date:  2021-09-09       Impact factor: 2.952

5.  Non-transplantable recurrence after percutaneous thermal ablation of ≤3-cm HCC: Predictors and implications for treatment allocation.

Authors:  Cecilia Gozzo; Margaux Hermida; Astrid Herrero; Fabrizio Panaro; Christophe Cassinotto; Azhar Meerun Mohamad; Eric Assenat; Chloé Guillot; Carole Allimant; Valentina Schembri; Antonio Basile; Sébastien Dharancy; José Ursic-Bedoya; Boris Guiu
Journal:  Hepatol Commun       Date:  2022-08-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.